Condition
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07299695Phase 3Recruiting
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT05674994Phase 3RecruitingPrimary
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Showing all 2 trials